Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 10/20 | 0.55 |
| ▸ | CASP3 | P42574 | 3/20 | 0.54 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 1/20 | 0.51 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.51 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.51 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425695 | 1.00 | CASP1 (0.55) | CASP1CASP3CTRB1CTSBCTSK | |
| SCHEMBL7349773 | 0.89 | CTRB1 (0.50) | CASP1CTRB1CTSBCTSKPSMB1 | |
| SCHEMBL8458845 | 0.89 | CTRB1 (0.50) | CASP1CTRB1CTSBCTSKPSMB1 | |
| SCHEMBL10277666 | 0.87 | CTSK (0.51) | CASP1CTRB1CTSBCTSKPSMB1 | |
| SCHEMBL10277668 | 0.87 | CTSK (0.51) | CASP1CTRB1CTSBCTSKPSMB1 | |
| SCHEMBL25992762 | 0.87 | CTSK (0.51) | CASP1CTRB1CTSBCTSKPSMB1 | |
| SCHEMBL13173061 | 0.87 | CTRB1 (0.54) | CTRB1CTSBCTSKPSMB1PSMB5 | |
| SCHEMBL5275940 | 0.87 | CTSK (0.59) | CTRB1CTSBCTSKPSMB1PSMB5 | |
| SCHEMBL630290 | 0.87 | CTSB (0.66) | CTRB1CTSB | |
| SCHEMBL7298029 | 0.87 | CTRB1 (0.54) | CTRB1CTSBCTSKPSMB1PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3692028-B1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS INC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2022-06-16 | — | — | US | disclosed |
| US-11247987-B2 | Inhibiting ubiquitin specific peptidase 30 | FORMA THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200317658-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3692028-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | Forma Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019071073-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
| CN-106831734-A | A kind of total synthesis method of and agromycin A | 中国医学科学院医药生物技术研究所 | 2017-06-13 | — | — | CN | disclosed |
| US-20120010161-A1 | NOVEL AZAPEPTIDE OR AZAPEPTIDOMIMETIC COMPOUNDS INHIBITING BCRP AND/OR P-GP | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2012-01-12 | — | — | US | disclosed |
| EP-1082127-A4 | SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | WARNER LAMBERT CO (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-1082127-A1 | SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1$g(b) CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 2001-03-14 | — | — | EP | disclosed |
| EP-1073658-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999056765-A1 | SUCCINAMIDE INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME | WARNER-LAMBERT COMPANY (US) | 1999-11-11 | — | — | WO | disclosed |
| WO-1999054333-A1 | PYRAZOLOPYRIMIDINONE CGMP PDE5 INHIBITORS FOR THE TREATMENT OF SEXUAL DYSFUNCTION | PFIZER INC. (US) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | USP30, UCHL1, UCHL3 | CASP1 1503/4885CASP3 942/4885CTRB1 2183/4885 |
| US-11247987-B2 | Inhibiting ubiquitin specific peptidase 30 | USP30, UCHL1, UCHL3 | CASP1 1002/4885CASP3 503/4885CTRB1 1770/4885 |
| US-20200317658-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | USP30, UCHL1, UCHL3 | CASP1 1503/4885CASP3 942/4885CTRB1 2183/4885 |
| US-20120010161-A1 | NOVEL AZAPEPTIDE OR AZAPEPTIDOMIMETIC COMPOUNDS INHIBITING BCRP AND/OR P-GP | ABCB1, ABCB11, ABCC1 | CASP1 1526/4885CASP3 998/4885CTRB1 3627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.